Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4 + and CD8 + T cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1281-1288

  Guenterberg, Kristan D ^a,b   Lesinski, Gregory B ^a,b   Mundy Bosse, Bethany L ^a,b   Karpa, Volodymyr I ^a,b   Jaime Ramirez, Alena Cristina ^a,b   Wei, Lai ^a,b   Carson III, William E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Interferon; Interferon alpha; Suppressors of cytokine signaling; T cell

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; PHOSPHATE BUFFERED SALINE; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOMODULATION; KAPLAN MEIER METHOD; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MELANOMA; MELANOMA CELL; MITOGENESIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; T CELL DEPLETION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; INTERFERON-ALPHA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES;

EID: 80054705401     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1034-2     Document Type: Article

References (28)

1. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150(2):179-185 (Pubitemid 38352453)
2. Atkins MB (1998) Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 12(4):877-902 viii (Pubitemid 28410381)
3. Saleh FH, Crotty KA, Hersey P, Menzies SW, Rahman W (2003) Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol 200(3):383-395 (Pubitemid 36827313)
4. Darnell JE Jr (1998) Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res 18(8):549-554 (Pubitemid 28391580)
5. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421 (Pubitemid 24217131)
6. Haque SJ, Williams BR (1998) Signal transduction in the interferon system. Semin Oncol 25(Suppl 1):14-22 (Pubitemid 28093151)
7. Ransohoff RM (1998) Cellular responses to interferon's and other cytokines: the JAK-STAT paradigm. N Engl J Med 338(9): 616-618 (Pubitemid 28114653)
8. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE III (2003) The antitumor effects of IFN-αlpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112(2):170-180 (Pubitemid 38056353)
9. Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, Walker MJ, Carson WE III (2005) Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 54(9):815-825 (Pubitemid 40991324)
10. Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2(6):410-416 (Pubitemid 37328748)
11. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA (1999) Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 18(2):375-385 (Pubitemid 29041946)
12. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18(5):1309-1320 (Pubitemid 29110315)
13. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A, Ihle JN (1999) SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98(5):609-616 (Pubitemid 29418952)
14. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A 95(24):14395-14399 (Pubitemid 28549378)
15. Berkelhammer J, Oxenhandler RW, Hook RR Jr, Hennessy JM (1982) Development of a new melanoma model in C57BL/6 mice. Cancer Res 42(8):3157-3163 (Pubitemid 12041072)
16. Gagnon J, Ramanathan S, Leblanc C, Ilangumaran S (2007) Regulation of IL-21 signaling by suppressor of cytokine signaling- 1 (SOCS1) in CD8(?) T lymphocytes. Cell Signal 19(4): 806-816 (Pubitemid 46275370)
17. Zimmerer JM, Lesinski GB, Kondadasula SV, Karpa VI, Lehman A, Raychaudhury A, Becknell B, Carson WE III (2007) IFNalpha- induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J Immunol 178(8): 4832-4845. doi:178/8/4832[pii] (Pubitemid 46595265)
18. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE III (2004) Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst 96(17):1331-1342 (Pubitemid 39264122)
19. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111(8):4233-4244
20. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168(2):689-695 (Pubitemid 34049569)
21. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709-718 (Pubitemid 43247141)
22. Moschos SJ, Kirkwood JM, Konstantinopoulos PA (2004) Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 22(1):11-14 (Pubitemid 41095107)
23. Catlett IM, Hedrick SM (2005) Suppressor of cytokine signaling 1 is required for the differentiation of CD4 ? T cells. Nat Immunol 6(7):715-721 (Pubitemid 41716745)
24. Chong MM, Cornish AL, Darwiche R, Stanley EG, Purton JF, Godfrey DI, Hilton DJ, Starr R, Alexander WS, Kay TW (2003) Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8 ? T cell differentiation. Immunity 18(4):475-487 (Pubitemid 36513630)
25. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, Torisu T, Hanada T, Yasukawa H, Fukuyama S, Inoue H, Nakanishi Y, Kobayashi T, Yoshimura A (2008) Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 180(6): 3746-3756
26. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY (2006) SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 116(1):90-100 (Pubitemid 43121794)
27. Hashimoto M, Ayada T, Kinjyo I, Hiwatashi K, Yoshida H, Okada Y, Kobayashi T, Yoshimura A (2009) Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci 100(4):730-736
28. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, Kato S, Yoshimura A (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203(6):1391-1397 (Pubitemid 43877600)